| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEWS |
From the *Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and Weill Medical College of Cornell University, New York, New York.
Address reprint requests to: Phyllis August, MD, MPH, Weill Medical College of Cornell University, 525 East 68th Street, New York, New York 10021; e-mail: paugust{at}med.cornell.edu.
OBJECTIVE: To assess the relationship between the factor V Leiden (1691 G-A) single nucleotide polymorphism (SNP), the methylene tetrahydrofolate reductase (MTHFR) 677 C–T SNP, and the prothrombin 20210 G-A SNP and the risk of preeclampsia, by conducting a meta-analysis of all case-control studies with data on these polymorphisms and the risk of preeclampsia.
DATA SOURCES: MEDLINE (1966 to November 2002), EMBASE (1980 to November 2002). Search terms included "preeclampsia," "thrombophilia," "factor V Leiden," "protein C," "MTHFR," "methylenetetrahydrofolate reductase," "homocysteine," and "prothrombin gene 20210."
METHODS OF STUDY SELECTION: Case-control studies of genetic thrombophilias and preeclampsia were included.
TABULATION, INTEGRATION, AND RESULTS: We identified 349 titles and reviewed 47 articles for inclusion and exclusion criteria. Thirty-one studies with 7,522 patients were included in the meta-analysis. Data from patients characterized as having severe preeclampsia were extracted and analyzed separately. The pooled odds ratio (OR) for the association of factor V Leiden and all cases of preeclampsia was 1.81 (95% confidence interval [CI] 1.14–2.87) and 2.24 (95% CI 1.28–3.94) for cases of severe preeclampsia. The pooled OR for the MTHFR 677 TT genotype and all preeclampsia was 1.01 (95% CI 0.79–1.29) and 1.38 (95% CI 0.93–2.06) for severe preeclampsia. The OR for the prothrombin 20210 polymorphism and all preeclampsia was 1.37 (95% CI 0.72–2.57) and 1.98 (.94–4.17) for severe preeclampsia.
CONCLUSION: This meta-analysis suggests that the factor V Leiden SNP is associated with an increased risk of preeclampsia. Further studies are warranted to determine whether subgroups of high-risk women should be screened for this mutation.
This article has been cited by other articles:
|
|
 |
|
  J. P. A. Ioannidis Effect of Formal Statistical Significance on the Credibility of Observational Associations Am. J. Epidemiol., August 15, 2008; 168(4): 374 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Nelson and I. A. Greer The potential role of heparin in assisted conception Hum. Reprod. Update, August 12, 2008; (2008) dmn031v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Barton and B. M. Sibai Prediction and Prevention of Recurrent Preeclampsia Obstet. Gynecol., August 1, 2008; 112(2): 359 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bellamy, J.-P. Casas, A. D Hingorani, and D. J Williams Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis BMJ, November 10, 2007; 335(7627): 974 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Ilekis, U. M. Reddy, and J. M. Roberts Review Article: Preeclampsia A Pressing Problem: An Executive Summary of a National Institute of Child Health and Human Development Workshop Reproductive Sciences, September 1, 2007; 14(6): 508 - 523. [Abstract] [PDF]
|
|
|
|
|
|
F. Stonek, E. Hafner, K. Philipp, L. A. Hefler, E.-K. Bentz, and C. B. Tempfer Methylenetetrahydrofolate Reductase C677T Polymorphism and Pregnancy Complications Obstet. Gynecol., August 1, 2007; 110(2): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Lockwood, P. Toti, F. Arcuri, E. Norwitz, E. F. Funai, S.-T. J. Huang, L. F. Buchwalder, G. Krikun, and F. Schatz Thrombin Regulates Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) Expression in First Trimester Decidua: Implications for Preeclampsia Am. J. Pathol., April 1, 2007; 170(4): 1398 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nurk, G.S. Tell, H. Refsum, P.M. Ueland, and S.E. Vollset Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study QJM, May 1, 2006; 99(5): 289 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sood, S. Kalloway, A. E. Mast, C. J. Hillard, and H. Weiler Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells Blood, April 15, 2006; 107(8): 3173 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Bockenstedt Management of Hereditary Hypercoagulable Disorders Hematology, January 1, 2006; 2006(1): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Sibai Thrombophilia and Severe Preeclampsia: Time to Screen and Treat in Future Pregnancies? Hypertension, December 1, 2005; 46(6): 1252 - 1253. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
